1c:{"metadata":[["$","title","0",{"children":"NIH VideoCast - Workshop - Evaluation of New Vaccines: How Much Safety Data? (Day 1)"}],["$","meta","1",{"name":"description","content":"FDA/Center for Biologics Evaluation and Research

\nThe motivation for this workshop arises from the importance of ensuring that optimal approaches are taken to the safety evaluation of new vaccines. While it is clear that very rare adverse reactions to vaccines will not likely ever be identifiable in randomized, controlled trials performed in support of licensure, the threshold for adverse event rates that should be reliably detected in these trials is worthy of discussion. This workshop will address the feasibility and desirability of performing larger prelicensure trials of vaccines in order to provide more precise measures of safety prior to widespread use. It will also invite discussion of the optimal balance between pre-licensure and post-licensure evaluation of vaccine safety.

\n\nFor more information, visit
\nWorkshop - Evaluation of New Vaccines: How Much Safety Data?
\n\n\n\n\n"}],["$","meta","2",{"name":"publisher","content":"National Institutes of Health"}],["$","meta","3",{"property":"og:title","content":"NIH VideoCast - Workshop - Evaluation of New Vaccines: How Much Safety Data? (Day 1)"}],["$","meta","4",{"property":"og:description","content":"FDA/Center for Biologics Evaluation and Research

\nThe motivation for this workshop arises from the importance of ensuring that optimal approaches are taken to the safety evaluation of new vaccines. While it is clear that very rare adverse reactions to vaccines will not likely ever be identifiable in randomized, controlled trials performed in support of licensure, the threshold for adverse event rates that should be reliably detected in these trials is worthy of discussion. This workshop will address the feasibility and desirability of performing larger prelicensure trials of vaccines in order to provide more precise measures of safety prior to widespread use. It will also invite discussion of the optimal balance between pre-licensure and post-licensure evaluation of vaccine safety.

\n\nFor more information, visit
\nWorkshop - Evaluation of New Vaccines: How Much Safety Data?
\n\n\n\n\n"}],["$","meta","5",{"property":"og:url","content":"https://uat.d1rkikwu4q8tg.amplifyapp.com/watch/96cfd603-d5db-11f0-9cf9-12c45c580ad9"}],["$","meta","6",{"property":"og:site_name","content":"NIH VideoCast"}],["$","meta","7",{"property":"og:image","content":"https://nihcit.rev.vbrick.com/api/v2/media/videos/thumbnails/16d2c399-8490-4be3-874b-b87fc9ec8721.jpg"}],["$","meta","8",{"property":"og:type","content":"website"}],["$","meta","9",{"name":"twitter:card","content":"summary_large_image"}],["$","meta","10",{"name":"twitter:title","content":"NIH VideoCast - Workshop - Evaluation of New Vaccines: How Much Safety Data? (Day 1)"}],["$","meta","11",{"name":"twitter:description","content":"FDA/Center for Biologics Evaluation and Research

\nThe motivation for this workshop arises from the importance of ensuring that optimal approaches are taken to the safety evaluation of new vaccines. While it is clear that very rare adverse reactions to vaccines will not likely ever be identifiable in randomized, controlled trials performed in support of licensure, the threshold for adverse event rates that should be reliably detected in these trials is worthy of discussion. This workshop will address the feasibility and desirability of performing larger prelicensure trials of vaccines in order to provide more precise measures of safety prior to widespread use. It will also invite discussion of the optimal balance between pre-licensure and post-licensure evaluation of vaccine safety.

\n\nFor more information, visit
\nWorkshop - Evaluation of New Vaccines: How Much Safety Data?
\n\n\n\n\n"}],"$L22","$L23","$L24"],"error":null,"digest":"$undefined"}